SCHEDULE 13G/A: Venrock Funds Maintain Significant 8.3% Stake in Mersana Therapeutics
Beneficial Ownership Disclosure
Venrock Healthcare Capital Partners and affiliated entities have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 8.3% of Mersana Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- The filing is an Amendment No. 2 to Schedule 13G, disclosing beneficial ownership of Mersana Therapeutics, Inc. common stock.
- The reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively own 10,257,790 shares.
- This aggregate ownership represents 8.3% of Mersana Therapeutics' outstanding common stock.
- The percentage is calculated based on 123,532,909 shares of common stock outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q filed on November 13, 2024.
- The shares are held across three primary entities: VHCP III (2,696,774 shares), VHCP Co-Investment III (269,783 shares), and VHCP EG (7,291,233 shares).
- The reporting persons are members of a group for the purposes of this Schedule 13G and certify that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing disclosing beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook. It simply confirms an existing significant stake.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a significant passive ownership stake by a healthcare-focused investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather confirms an existing institutional investment position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming a large, passive ownership position.
Key Dates
| Date | Description |
|---|---|
| 2024-11-08 | Date as of which Mersana Therapeutics' common stock outstanding (123,532,909 shares) was reported in their Form 10-Q. |
| 2024-11-13 | Date Mersana Therapeutics filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date the Joint Filing Agreement was executed and the Schedule 13G/A was signed. |
Keywords
Mersana Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.